POPULAR SEARCH TERMS: Influenza Vaccines Careers Pandemic Preparedness Expertise Search Results Label 91 results found EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day https://www.seqirus.com/news/eu-flu-day-2021 Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic https://www.seqirus.com/news/first-shipment-2021-22 The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age https://www.seqirus.com/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children Seqirus | About Influenza Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines. https://www.seqirus.com/expertise/influenza Seqirus | Vaccine Technologies Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology. https://www.seqirus.com/manufacturing/technologies Seqirus | Influenza Expertise Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs. https://www.seqirus.com/expertise Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives https://www.seqirus.com/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA) Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza. https://www.seqirus.com/news/seqirus-invests-in-self-amplifying-messenger-rna-technology Seqirus | A World Leader in Influenza Vaccines Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats. https://www.seqirus.com/ Seqirus | Our Products Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community. https://www.seqirus.com/products 12345678 Report an Adverse Event Cookie Policy Privacy Notice Modern Slavery Terms of Use Sitemap © 2021 Seqirus. All rights reserved. Seqirus is a trademark of Seqirus UK Limited or its affiliates. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies